This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GRT 6006
Description: GRT 6006 is a follow-on compound to GRT 6005. Both compounds are novel first in class compounds with potent agonist activity on ORL-1 (opioid receptor like -1) and the mu opioid receptor.
Grunenthal and Forest
In December 2010, the Grunenthal Group and Forest Laboratories announced that Grunenthal GmbH and Forest Laboratories Ireland Limited have entered into a license agreement for the co-development and commercialization of GRT 6005 and GRT 6006.
The license agreement provides that Forest pay Gruenenthal an undisclosed upfront license payment in addition to development and commercialization milestones and royalties on net sales. Under the agreement, Forest will have exclusive rights in the United States and Canada with an option to co-promote in Europe. Gruenenthal will have an option to co-promote in the United States and Canada. Development costs will be shared between the parties according to an undisclosed formula.
Forest and Actavis
In February 2014, Actavis and Forest announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at...See full deal structure in Biomedtracker
Partners: Grünenthal GmbH
GRT 6006 News
Additional information available to subscribers only: